
Andrew J Mungall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11687123/publications.pdf Version: 2024-02-01



ANDREWIMUNCALL

#	Article	IF	CITATIONS
1	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood, 2021, 137, 2196-2208.	0.6	18
2	A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nature Communications, 2021, 12, 2474.	5.8	49
3	Modulation of the Host Cell Transcriptome and Epigenome by Fusobacterium nucleatum. MBio, 2021, 12, e0206221.	1.8	10
4	Sample Tracking Using Unique Sequence Controls. Journal of Molecular Diagnostics, 2020, 22, 141-146.	1.2	10
5	Epigenomic programming in early fetal brain development. Epigenomics, 2020, 12, 1053-1070.	1.0	9
6	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588.	15.2	46
7	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood, 2020, 136, 572-584.	0.6	44
8	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	2.9	74
9	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 190-201.	0.8	257
10	Sources of erroneous sequences and artifact chimeric reads in next generation sequencing of genomic DNA from formalin-fixed paraffin-embedded samples. Nucleic Acids Research, 2019, 47, e12-e12.	6.5	50
11	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood, 2019, 133, 1313-1324.	0.6	172
12	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. Journal of Molecular Diagnostics, 2018, 20, 203-214.	1.2	58
13	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
14	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	13.5	1,718
15	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	13.5	228
16	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	13.5	272
17	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	13.5	1,417
18	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	2.9	333

ANDREW J MUNGALL

#	Article	IF	CITATIONS
19	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	2.9	407
20	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	2.9	801
21	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	7.7	750
22	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 2018, 24, 103-112.	15.2	525
23	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nature Communications, 2018, 9, 4001.	5.8	102
24	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	2.1	23
25	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
26	Characterization of the human thyroid epigenome. Journal of Endocrinology, 2017, 235, 153-165.	1.2	8
27	MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 3964-3977.	0.8	49
28	Analysis of Normal Human Mammary Epigenomes Reveals Cell-Specific Active Enhancer States and Associated Transcription Factor Networks. Cell Reports, 2016, 17, 2060-2074.	2.9	90
29	Large-scale profiling of microRNAs for The Cancer Genome Atlas. Nucleic Acids Research, 2016, 44, e3-e3.	6.5	125
30	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. Cancer Cell, 2016, 29, 394-406.	7.7	105
31	Recurrent genomic rearrangements in primary testicular lymphoma. Journal of Pathology, 2015, 236, 136-141.	2.1	47
32	Integrative analysis of 111 reference human epigenomes. Nature, 2015, 518, 317-330.	13.7	5,653
33	Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biology, 2015, 16, 18.	3.8	107
34	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
35	Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. Science, 2014, 343, 189-193.	6.0	1,147
36	A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood, 2014, 123, 3914-3924.	0.6	69

ANDREW J MUNGALL

#	Article	IF	CITATIONS
37	Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics, 2013, 14, 550.	1.2	12
38	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood, 2013, 121, 3666-3674.	0.6	139
39	Complete genomic landscape of a recurring sporadic parathyroid carcinoma. Journal of Pathology, 2013, 230, 249-260.	2.1	57
40	Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine, 2013, 368, 2059-2074.	13.9	4,139
41	DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nature Genetics, 2013, 45, 836-841.	9.4	207
42	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood, 2013, 122, 1256-1265.	0.6	349
43	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood, 2012, 119, 4949-4952.	0.6	60
44	Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget, 2012, 3, 1308-1319.	0.8	127
45	Concurrent <i>CIC</i> mutations, <i>IDH</i> mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Journal of Pathology, 2012, 226, 7-16.	2.1	272
46	Mutations in EZH2 Cause Weaver Syndrome. American Journal of Human Genetics, 2012, 90, 110-118.	2.6	253
47	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature, 2011, 476, 298-303.	13.7	1,428
48	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood, 2011, 117, 2451-2459.	0.6	556
49	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics, 2010, 42, 181-185.	9.4	1,504